NRx Pharmaceuticals announced September 15 that FDA reclassified an amendment to its Abbreviated New Drug Application for preservative-free ketamine from Major to Minor, moving the review’s goal date to November 10, 2026. Jonathan Javitt, whom the release identifies as chairman and chief executive, said the company was appreciative of the speed with which FDA’s leadership had moved to advance what he described as a strategic, drug-shortage product. NRx’s own prior SEC filings describe a narrower sequence: the amendment became a Major one after FDA flagged the cap on NRx’s own vial as a major container-closure deficiency, and the new date is still later than the one FDA had set before that issue surfaced.
What happened, in order
NRx refiled its ANDA for the product, branded KETAFREE, after FDA granted a suitability petition in September 2025. A suitability petition is the mechanism a generic applicant needs before FDA will accept an ANDA for a product that differs from the reference-listed drug; per NRx’s own announcement, the granted petition covers the single-patient-dose strength the company proposed, enabling a shift from multidose packaging to a single-patient, preservative-free presentation. FDA received the refiled application with an original GDUFA goal date of July 29, 2026, according to NRx’s own December 2025 disclosure. That date passed. On July 30, per an 8-K NRx filed August 7, FDA found no major deficiencies related to the product’s drug components but identified a major deficiency in the vial’s twist-off, luer-lock cap, where a reviewer expressed concern the vial tip could deform in clinical use; the filing states the classification as major is required because the matter affects the container closure. A Major Amendment typically carries an eight-to-ten-month goal date from the point of reclassification, which would have pushed a decision into the first half of 2027. The September 15 reclassification back to Minor, with a roughly three-month clock, sets the new goal date at November 10, 2026, faster than the Major-amendment scenario, but still more than three months past the date FDA had assigned before the cap issue existed.
What “drug shortage product” does and does not establish
FDA’s drug shortage database currently carries ketamine hydrochloride injection as a discontinuation entry, a Pfizer multiple-dose presentation reported discontinued from manufacture in November 2025; it does not appear in the database’s currently-in-shortage list. NRx’s own August filing describes ketamine as appearing on the current FDA drug shortage list, and the September 15 release calls it a strategic, drug-shortage product; the database’s present status is the narrower fact. Nor is NRx’s own candidate a shortage product in any direct sense. NRx’s preservative-free formulation is not an approved, marketed drug, so it cannot itself be in shortage; it is an unapproved candidate the company is positioning as supply relief for a market where an incumbent presentation has been discontinued, once and if it clears FDA review. That distinction matters for readers pricing how close this brings a shortage fix: an ANDA nearing its goal date is a regulatory milestone, not a supply event, and FDA reaching a decision by November 10 would still be followed by manufacturing and distribution before any vial reaches a hospital pharmacy.
Two different regulatory tracks, not one
The ANDA covered by the September 15 release is separate from NRx’s other stated regulatory path for the same drug substance. The company says it has separately initiated a New Drug Application filing for NRX-100, the same preservative-free ketamine, specifically for suicidal ideation in patients with depression, including bipolar depression, an indication that already carries FDA Fast Track Designation granted in August 2025. NRx has also applied for, but has not been granted, a Commissioner’s National Priority Voucher for that NDA, a distinction the company’s own release preserves accurately in its wording. The ANDA is a generic-style filing aimed at supply relief for a shortage-affected formulation already on the market in a different form; the NDA is a branded, indication-specific filing seeking to establish a new approved use. Progress on one does not establish progress on the other, and the September 15 news is about the ANDA only.
The financial backdrop
NRx’s enthusiasm for a modest procedural reclassification arrives against a specific balance-sheet context. The company’s 10-Q for the quarter ended March 31, 2026 included explicit going-concern language expressing substantial doubt about NRx’s ability to continue operating, with $6.7 million in cash and cash equivalents at that quarter’s end. By June 30, 2026, cash and cash equivalents had risen to $26.7 million, following an underwritten public offering that closed in June with $22.3 million in gross proceeds, a figure the company disclosed in its August 17 results filing. The most recent 10-Q, filed August 14, still concludes that substantial doubt exists about the company’s ability to continue as a going concern, while stating that secured capital is anticipated to fund drug-development operations through at least the first quarter of 2027. A company in that position has more reason than a better-capitalized peer to treat a three-month acceleration in a review clock as meaningfully positive news, even when that acceleration is measured against a worse-case scenario created by its own packaging issue, not against the date FDA originally assigned.
A loose end in the release itself
The September 15 release lists a Zeta Surgical media address as its media contact, alongside NRx’s usual investor-relations firm, and carries boilerplate describing Zeta Surgical and HOPE Therapeutics, material consistent with carryover from the company’s September 11 announcement that HOPE, NRx’s majority-owned subsidiary, had begun deploying Zeta’s FDA-cleared robotic TMS system at its clinics. That commercial relationship is documented across several 2026 NRx releases; the public record shows no ownership or equity relationship between NRx and Zeta Surgical. The template artifacts do not change the underlying regulatory facts, but they are an unusual feature for a company-specific FDA announcement, and worth noting instead of passing over silently.
What to watch
The November 10, 2026 GDUFA goal date is the next concrete checkpoint, and it marks a decision point, not a guaranteed approval; FDA can still issue a complete response instead of approving on that date. Separately, and on its own timeline, NRX-100’s NDA filing and its pending National Priority Voucher application address a different question entirely, whether the same drug substance secures a new, branded psychiatric indication, a track that this ANDA news does not advance and should not be read as advancing.